GLP-1 Lawsuit Lawyer: Eligibility, Payouts, and Deadlines

If you took Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, or Trulicity and suffered a serious gastrointestinal injury or sudden vision loss, a GLP-1 lawsuit lawyer can evaluate whether you qualify to join the ongoing federal litigation against Novo Nordisk or Eli Lilly. More than 4,700 injury cases are already consolidated in federal court in Philadelphia, and attorneys are still accepting new claims.{¹}

What follows is what a lawyer will actually ask you about, what documents you will need, and where the litigation stands.

Which Drugs and Injuries Qualify

The lawsuits target two manufacturers. Novo Nordisk makes the semaglutide drugs Ozempic, Wegovy, and Rybelsus, along with Saxenda. Eli Lilly makes tirzepatide-based Mounjaro and Zepbound, along with the older GLP-1 drug Trulicity.{²} All of these FDA-approved brand-name products are eligible.{³}

Qualifying injuries fall into two groups. The first is severe gastrointestinal harm: gastroparesis (stomach paralysis), ileus, intestinal or bowel obstruction, pancreatitis, gallbladder disease requiring surgery, and chronic vomiting severe enough to require hospitalization.{} The second is vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION), a condition that damages the optic nerve and can cause sudden, permanent blindness.{⁴}

The core legal theory is failure to warn. Plaintiffs allege the manufacturers knew or should have known about these risks but did not adequately disclose them on drug labels or in marketing.{⁵} An ileus warning was added to some labels in September 2023; a broader severe-GI warning was added to Wegovy in November 2024 and to Ozempic in October 2025.{⁶}{⁷} On vision loss, plaintiffs allege the labels still carry no meaningful NAION warning.{⁴}

A boundary worth knowing before you call a lawyer: compounded or generic versions of semaglutide and tirzepatide are generally not part of the MDL litigation.{³} If your medication came from a compounding pharmacy, medical spa, or telehealth platform rather than a standard retail pharmacy prescription for a brand-name product, your case may not qualify for the current consolidated proceedings.

What You Need to Document

These are individual lawsuits, not a class action. Each person’s case rises or falls on their own records.{¹} A lawyer screening your claim will typically want four things:

Prescription or pharmacy records proving you actually took a qualifying brand-name drug.
A formal diagnosis from a physician for one of the qualifying conditions.
Objective diagnostic testing in your medical records. For gastroparesis claims, this means a gastric emptying study.
A timeline showing symptoms appeared or worsened during or shortly after drug use, with no significant pre-existing history of the same condition.{}³

The gastric emptying study requirement is not a technicality. On August 15, 2025, Judge Karen S. Marston excluded plaintiffs’ expert testimony that attempted to diagnose drug-induced gastroparesis from clinical symptoms alone. The court found that diagnosing gastroparesis without a gastric emptying study was “at odds with the medical consensus” and did not meet Federal Rule of Evidence 702’s reliability standard.{} About 95% of MDL claims allege gastroparesis, so this ruling filters heavily.{⁸} If you believe you have drug-induced gastroparesis but have never had a gastric emptying study, that is the test to ask your doctor about before filing.

The same ruling struck medical monitoring and design defect theories, but failure-to-warn and breach-of-warranty claims are still moving forward.{⁹}

Deadline to File

Statutes of limitations vary by state and range from one to six years. Many states apply a discovery rule, meaning the clock starts when you knew or reasonably should have known your injury was connected to the medication. As of mid-2026, the litigation is still actively accepting new plaintiffs.{¹} Because the applicable window depends on your state and when you connected your symptoms to the drug, a lawyer needs to check the deadline against your specific facts before anything else.

Where Your Case Would Be Filed

Federal cases are consolidated in the U.S. District Court for the Eastern District of Pennsylvania before Judge Marston, in two separate multidistrict litigations. MDL 3094 handles gastrointestinal injury claims and had more than 4,706 pending cases as of April 2026.{¹} MDL 3163, authorized in December 2025, handles NAION vision-loss cases involving Ozempic, Wegovy, Saxenda, and Trulicity.{¹⁰}

More than 1,200 additional cases are pending in state courts, with the larger dockets in New Jersey, Indiana, and Delaware.{¹¹} Your lawyer will decide where to file based on your residence, where you were prescribed and used the drug, and strategic factors particular to your claim.

What a Case Might Be Worth

No GLP-1 case has settled or gone to trial, so any figure you see is a projection, not a payout. With that caveat clearly in mind, attorneys have published tiered estimates based on injury severity and comparisons to earlier pharmaceutical mass torts:

Severe gastroparesis requiring feeding tubes, repeated hospitalizations, or permanent dietary changes: roughly $400,000 to $700,000.{}¹²
NAION resulting in permanent blindness: projected to exceed $1 million, potentially $1.5 million or more.{}{}¹²¹³
Significant GI injuries requiring emergency care or hospitalization without permanent disability: roughly $150,000 to $400,000.{}¹³
Documented side effects managed through outpatient treatment: roughly $50,000 to $150,000.{}¹³

Some analysts have suggested total manufacturer liability could exceed $2 billion across all claims.{¹²} These are educated guesses. Your actual outcome will depend on the strength of your medical documentation, bellwether trial results, and whether a global settlement materializes.

When Money Might Actually Arrive

Nothing is imminent. In January 2026 the court issued Case Management Order No. 30 setting expert disclosure and Daubert deadlines, and bellwether cases (a small group of representative trials whose outcomes guide broader settlement talks) are being selected.{¹} Bellwether trials are expected to begin in the second half of 2026 or in early 2027.{¹⁴}{¹⁵}

Serious settlement negotiations are not expected to open before those bellwether results, likely mid-2027 at the earliest, with final resolutions potentially stretching into 2028 or 2029.{¹⁵} Filing now preserves your place; it does not accelerate a check.

The manufacturers are fighting. Both Novo Nordisk and Eli Lilly deny liability, saying their drugs are safe when used as directed and carry FDA-approved warnings.{²} They have argued federal preemption and, at a Science Day presentation, contended that GLP-1 drugs only temporarily slow gastric emptying rather than cause a diagnosable condition, and may “unmask” pre-existing problems.{¹}

How the Fees Work

Mass tort lawyers in these cases typically take claims on contingency, meaning no fee unless you recover. On top of your lawyer’s contingency percentage, Case Management Order No. 17 requires that if there is any settlement or verdict, 9% of the gross recovery goes to a common benefit fund for the leadership attorneys handling the shared work of the MDL, and 2% goes to a common benefit expense fund.{⁹} That 11% comes out of the gross recovery before your individual attorney’s fee and your net share are calculated. Ask any lawyer you interview to walk through exactly how their fee interacts with the common benefit assessment.

What to Do Next

Pull together what you already have: pharmacy records or a list of prescriptions with dates, the name of the drug you took, the diagnosis you received, and the names of any hospitals or specialists who treated you. If you believe you have drug-induced gastroparesis and no gastric emptying study is in your file, raise the test with your treating physician; without it, the case is unlikely to survive under the August 2025 ruling. Then contact a lawyer who handles GLP-1 cases and confirm your state’s filing deadline against your own timeline of symptoms and diagnosis.

1
Wagstaff and Cartmell. GLP-1 Multidistrict Litigation MDL 3094: What Injured Patients Need to Know
2
NewsNation. GLP-1 Drugmakers Side Effects Lawsuit
3
Defective Drug Site. GLP-1 Drugs Lawsuit Criteria
4
Drugwatch. Ozempic Lawsuit
5
The Indiana Lawyer. Lilly, Novo Nordisk Sued for Alleged Failure to Warn About Severe Side Effects of Popular Diabetes Drugs
6
U.S. Food and Drug Administration. Wegovy Prescribing Information
7
U.S. Food and Drug Administration. Ozempic Prescribing Information
8
Drug and Device Law Blog. Trimming Down the GLP-1 MDL
9
Miller & Zois. Ozempic Gallbladder Lawsuit
10
Motley Rice. GLP-1 Lawsuit Update: Vision Loss Litigation Consolidated
11
USA Today. GLP-1 Weight Loss Drug Lawsuits Side Effects
12
TruLaw. Ozempic Lawsuits Possible Compensation for Damages
13
Slepkow Law. Ozempic Lawsuit Settlement Amounts
14
LawFold. GLP-1 Lawsuit
15
Helbock Law. Ozempic Lawsuit Settlement Timeline